标题
Teclistamab‐cqyv in multiple myeloma
作者
关键词
-
出版物
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-10-18
DOI
10.1111/ejh.14121
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
- (2023) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- GPRC5D as a novel immunotherapeutic target in multiple myeloma
- (2023) Karthik Nath et al. Nature Reviews Clinical Oncology
- Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
- (2023) Philippe Moreau et al. ADVANCES IN THERAPY
- Belantamab mafodotin in multiple myeloma
- (2023) Enrica Antonia Martino et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Isatuximab in multiple myeloma
- (2023) Enrica Antonia Martino et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT).
- (2023) Priyanka Venkatesh et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies.
- (2023) Urvi Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
- (2023) Ross Firestone et al. JOURNAL OF CLINICAL ONCOLOGY
- LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
- (2023) Hans C. Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.
- (2023) Niels W.C.J. van de Donk et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
- (2023) Niels W.C.J. van de Donk et al. JOURNAL OF CLINICAL ONCOLOGY
- First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- (2023) Yael C Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
- (2023) Thomas Martin et al. Blood Cancer Journal
- Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials
- (2023) Massimo Gentile et al. HAEMATOLOGICA
- Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
- (2022) Antonella Bruzzese et al. HEMATOLOGICAL ONCOLOGY
- Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
- (2022) Enrica Antonia Martino et al. HEMATOLOGICAL ONCOLOGY
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
- (2022) Maria-Victoria Mateos et al. LEUKEMIA
- Teclistamab in Relapsed or Refractory Multiple Myeloma
- (2022) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
- (2022) Anita D'Souza et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
- (2022) Nizar Jacques Bahlis et al. BLOOD
- RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
- (2022) Carmelo Carlo-Stella et al. BLOOD
- MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant
- (2022) Amrita Y. Krishnan et al. BLOOD
- Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
- (2022) Diana Cortes-Selva et al. BLOOD
- Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program
- (2022) Katarina Uttervall et al. BLOOD
- Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
- (2022) Sanjay R Mohan et al. BLOOD
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
- (2022) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
- (2022) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
- (2021) Sagar Lonial et al. CANCER
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study
- (2021) Suzanne Trudel et al. BLOOD
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
- (2021) Saad Z Usmani et al. LANCET ONCOLOGY
- Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab
- (2020) Kristine A. Frerichs et al. CLINICAL CANCER RESEARCH
- Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
- (2020) Massimo Gentile et al. HAEMATOLOGICA
- Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
- (2020) Kodandaram Pillarisetti et al. Blood Advances
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination
- (2019) Ilseyar Akhmetzyanova et al. LEUKEMIA
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Pomalidomide in multiple myeloma
- (2016) Giuseppina Uccello et al. EXPERT OPINION ON PHARMACOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now